High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Investing.com -- Artificial intelligence is moving beyond text generation into scientific research, creating investment opportunities across AI infrastructure, pharmaceuticals, nuclear fusion, industrial materials and utilities, according to UBS Wealth Management.
These companies may perform well in any market environment.
Eli Lilly & Co. has surged about 300% since its first GLP-1 was approved over four years ago, propelling it past $1 trillion in market value and making it the world’s most valuable pharmaceutical company.
Eli Lilly (NYSE:LLY) has entered an exclusive research collaboration with QurCan Therapeutics to develop genetic medicines for nervous system diseases. The agreement centers on QurCan's polymer lipid nanoparticle delivery platform for central and peripheral nervous system targets, with Eli Lilly responsible for later development and commercialization. Lilly is also making a strategic investment in QurCan Therapeutics, tying capital directly to progress in genetic medicine delivery...
LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.
One fast-growing business could push results above guidance
Foundayo's diabetes approval is expected to unlock demand after a slow start
Berenburg upgrades Eli Lilly stock to Buy from Hold, citing growth prospects fueled by its weight-loss drugs.
Eli Lilly (NYSE:LLY) shares rose 1. 6% to $1,155.
Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is clean but short. That record asks for the better part of a year and more pain before it pays. And this fall is not the kind of fall that record is built on.
Eli Lilly and Nvidia both just posted stunning quarters riding two of the biggest secular waves in markets today, but a $10,000 bet can only tilt one way. Which secular story holds the sharper edge heading into 2026?
Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether this pharmaceutical giant still has meaningful upside left.
PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.
Shifting emphasis from symptoms to biomarkers has bolstered sector confidence in emerging CNS therapies.
According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.
Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.
The maker of Mounjaro and Zepbound just signed its 13th deal of the year.
LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.
GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
Eli Lilly and Co (NYSE:LLY) said on Monday it will acquire privately held Merida Biosciences for up to $2.88 billion in cash, part of a deal-making push to broaden its treatments for immune-related and allergic diseases. The acquisition continues a run of dealmaking for Lilly, whose deal...
Eli Lilly (LLY) has agreed to acquire Merida Biosciences for up to $2.875 billion in cash, as it see
The deal adds a pipeline targeting the antibodies behind Graves' disease, thyroid eye disease, food allergy, and other conditions
Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker’s immunology portfolio.
Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker’s immunology portfolio.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
